# TherapeuticsMD, Inc.: Form 10-Q for the period ended Jun 30, 2015

- Company: [TherapeuticsMD, Inc.](/companies/txmd.md) (CIK 25743)
- Form: 10-Q
- Filed: 2015-08-07
- Accepted by EDGAR: Aug 7, 2015, 16:49 ET
- Period: 2015-06-30
- Accession: 0001387131-15-002352
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/25743/000138713115002352/txmd-10q_063015.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/25743/000138713115002352/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-04-01 to 2015-06-30 | $4.8m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2015-01-01 to 2015-06-30 | $9.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-04-01 to 2015-06-30 | $1.0m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2015-01-01 to 2015-06-30 | $2.1m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2015-04-01 to 2015-06-30 | $3.8m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2015-01-01 to 2015-06-30 | $7.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2015-04-01 to 2015-06-30 | $24.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2015-01-01 to 2015-06-30 | $42.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2015-04-01 to 2015-06-30 | $6.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2015-01-01 to 2015-06-30 | $13.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | −$27.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-01-01 to 2015-06-30 | −$48.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2015-04-01 to 2015-06-30 | −$27.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-01-01 to 2015-06-30 | −$48.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | −$0.16 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2015-01-01 to 2015-06-30 | −$0.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2015-01-01 to 2015-06-30 | −$44.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2015-01-01 to 2015-06-30 | $15.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-06-30 | $67.2m | us-gaap:Cash |
| Current assets | at 2015-06-30 | $73.0m | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $75.7m | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $11.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-06-30 | $12.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-06-30 | $63.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/25743/000138713115002352/txmd-10q_063015.htm

Filed Aug 7, 2015.
Source: SEC EDGAR, the filing index for accession 0001387131-15-002352. Last ingested by Listed: Nov 14, 2026, 19:24 ET. No prices; not investment advice.
